GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BTAI · Dec 31, 2022

BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-23-003940General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

37.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-36090.93% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

529.33% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

94.67% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-42572.00% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

24330.40% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4623.20% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.00%
Current
37.07%
Delta
37.07%
Cash Generation Decreased
Previous
-22763.50%
Current
-36090.93%
Delta
-13327.43%
Inventory Pressure Decreased
Previous
1027.74%
Current
529.33%
Delta
-498.40%
Margin Increased
Previous
91.97%
Current
94.67%
Delta
2.70%
Profitability Decreased
Previous
-28459.85%
Current
-42572.00%
Delta
-14112.15%
R And D Intensity Increased
Previous
16103.65%
Current
24330.40%
Delta
8226.75%
Sbc Intensity Increased
Previous
3272.26%
Current
4623.20%
Delta
1350.94%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BTAI Fundamental State →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI CAPEX_INTENSITY_INCREASED →Transitioned To · BTAI CASH_GENERATION_DECREASED →Transitioned To · BTAI INVENTORY_PRESSURE_DECREASED →Transitioned To · BTAI MARGIN_INCREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.